Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients.
Caffo O, Lo Re G, Sava T, Buti S, Sacco C, Basso U, Zustovich F, Lodde M, Perin A, Facchini G, Veccia A, Maines F, Barile C, Fratino L, Gernone A, De Vivo R, Pappagallo GL, Galligioni E.
Caffo O, et al.
Future Oncol. 2015;11(6):965-73. doi: 10.2217/fon.14.284.
Future Oncol. 2015.
PMID: 25760977
Clinical Trial.